189 related articles for article (PubMed ID: 22565090)
1. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.
Leung JY; Barr AM; Procyshyn RM; Honer WG; Pang CC
Pharmacol Ther; 2012 Aug; 135(2):113-22. PubMed ID: 22565090
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
4. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T; Kin NM; Beaulieu S; de Baptista EA
Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.
Nasrallah HA
Mol Psychiatry; 2008 Jan; 13(1):27-35. PubMed ID: 17848919
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular effects of antipsychotics.
Michelsen JW; Meyer JM
Expert Rev Neurother; 2007 Jul; 7(7):829-39. PubMed ID: 17610390
[TBL] [Abstract][Full Text] [Related]
7. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms.
Reynolds GP; Kirk SL
Pharmacol Ther; 2010 Jan; 125(1):169-79. PubMed ID: 19931306
[TBL] [Abstract][Full Text] [Related]
8. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
Rzewuska M
Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
[TBL] [Abstract][Full Text] [Related]
9. Cardiac side effects of psychiatric drugs.
Mackin P
Hum Psychopharmacol; 2008 Jan; 23 Suppl 1():3-14. PubMed ID: 18098218
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risks of atypical antipsychotic drug treatment.
Drici MD; Priori S
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):882-90. PubMed ID: 17563919
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
12. [Atypical antipsychotic induced weight gain and metabolic disorders].
Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
[TBL] [Abstract][Full Text] [Related]
13. Preclinical models of antipsychotic drug-induced metabolic side effects.
Boyda HN; Tse L; Procyshyn RM; Honer WG; Barr AM
Trends Pharmacol Sci; 2010 Oct; 31(10):484-97. PubMed ID: 20674990
[TBL] [Abstract][Full Text] [Related]
14. Metabolic risk during antipsychotic treatment.
Newcomer JW
Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert M; Detraux J; van Winkel R; Yu W; Correll CU
Nat Rev Endocrinol; 2011 Oct; 8(2):114-26. PubMed ID: 22009159
[TBL] [Abstract][Full Text] [Related]
16. Interfaces of psychopharmacology and cardiology--Part two.
Risch SC; Groom GP; Janowsky DS
J Clin Psychiatry; 1981 Feb; 42(2):47-59. PubMed ID: 6109718
[TBL] [Abstract][Full Text] [Related]
17. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
Hasnain M; Fredrickson SK; Vieweg WV
J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
[TBL] [Abstract][Full Text] [Related]
18. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl SM; Mignon L; Meyer JM
Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
[TBL] [Abstract][Full Text] [Related]
19. Implementation of monitoring and management guidelines for second-generation antipsychotics.
Sernyak MJ
J Clin Psychiatry; 2007; 68 Suppl 4():14-8. PubMed ID: 17539695
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic-induced metabolic and cardiovascular side effects in schizophrenia: a novel mechanistic hypothesis.
Scigliano G; Ronchetti G
CNS Drugs; 2013 Apr; 27(4):249-57. PubMed ID: 23533011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
